Profile Summary

Medical Qualification: MBBS, MD, DM Medical Oncology, DrNB Medical Oncology, ECMO

Designation at JHRC: Consultant, Medical Oncology

Years of experience: 8 years

Areas of expertise:   

• Lung Cancer, Breast Cancer, Head and neck cancers, Ovarian cancers, Urological cancers, Gastrointestinal cancer
• Blood Cancers- Lymphomas, Multiple myeloma, Leukaemia
• Precision Oncology
• Chemotherapy
• Biological therapy- Molecular targeted therapy
• Immunotherapy
• Stem cell transplant therapy

Introduction:

Dr Sunil Chopade is a well experienced Medical Oncologist and Hemato Oncologist. 

Dr Chopade completed his under-graduation MBBS from GMC Nagpur and post-graduation in Internal medicine MD from IGGMC Nagpur. He then pursued his super speciality training DM in Medical Oncology from prestigious Institute Tata Memorial Centre, Mumbai.  After completing DM in 2019, he was working as Assistant Professor, Consultant Medical Oncology at TMH Mumbai.

Dr Sunil is well trained in medical management of solid organ cancers, lung cancer, breast cancer, head and neck cancers, ovarian cancer, gastrointestinal cancers, urinary cancers and rare cancers like thymomas, neuroendocrine tumour. He is specialised in treating haematological cancers, leukemias, lymphomas and multiple myeloma. He had  his training in hematopoetic stem cell therapy at ACTREC, TMC, Mumbai during his tenure. He has actively participated in the management and containment of COVID-19 in cancer patients and was member of COVID action team at TMH.

He has his expertise in conventional Chemotherapy, Molecular Targeted therapy, Immunotherapy, and Stem cell transplant therapy for various cancers. He is skilled in oncological procedures.

He received his DrNB in Medical Oncology from National Board of Examinations New Delhi in 2020. He is an ESMO (European Society of Medical Oncology) Certified Medical Oncologist. He is member of many national and international societies - ASCO (American Society of Clinical Oncology, ESMO (European Society of Medical Oncology), ISMPO (Indian Society of Medical and Paediatric Oncology), ICON (Indian Cooperative Oncology Network) AMC (Association of Medical Consultants), etc. 

He has interest in academics and research. He has been part of various clinical trials and research studies. He has been part of rare cancer clinics, precision medicine and molecular oncology clinics and multidisciplinary tumour boards. He has many research publications in national and international index journal like Journal of Clinical Oncology, Nature. He had presented research posters and abstracts at national and international conferences.

Awards & Publications:

Clinical Trials:

• Principal Investigator: Phase III study -“A two-arm: open label prospective parallel design Phase III clinical trial to evaluate the efficacy of a multidisciplinary patient navigation program and symptom monitoring with patient- reported outcomes in lung cancer patients”. Tata Memorial Centre, Mumbai, India 
• Co-Investigatior: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY Lung04), Tata Memorial Centre, Mumbai, India 
• Co-Investigator: Project Title - Prospective observational study to establish the duration of replication component of SARS-CoV-2 persistence in oncology patients on chemotherapy “ Tata Memorial Centre, Mumbai, India

Publications:

• Vanita Noronha, Anbarasan Sekar, Akhil Rajendra, Smruti Mokal, Vijay Patil, Nandini Menon, Sunil Chopade, Ajay Kumar Singh, Rajiv Kumar Kaushal, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Rajesh Dikshit, Shripad Banavali, Kumar Prabhash, Rajendra Badwe; Epidemiological Trend of Esophageal Cancer at a Tertiary Cancer Center in Mumbai, India, Over the Past 15 Years Journal of Gastrointestinal Cancer https://doi.org/10.1007/s12029-022-00887-z
•  Noronha, Vanita & Chougule, Anuradha & Chandrani, Pratik & Kaushal, Rajiv & Patil, Vijay & Menon, Nandini & Kapoor, Akhil & Chopade, Sunil & Singh, Ajaykumar & Shetty, Omshree & Dutt, Amit & Banavali, Shripad & Prabhash, Kumar. (2022). Lung cancer with dual EGFR and ALK driver alterations at baseline: a retrospective observational cohort study. Acta Oncologica. 1-5. 10.1080/0284186X.2022.2109426.
• Sunil Ramdhan Chopade, Vijay Maruti Patil, Vanita Noronha, Nandini Sharrel Menon, Atanu Bhattacharjee, Kavita Prakash Nawale, Shripad Dinanath Banavali, Kumar Prabhash, and Vijayalakshmi Mathrudev:   Phase III randomized control study evaluating adjuvant metronomic chemotherapy in locally advanced head and neck cancers post-radical chemoradiation (MACE-CTRT). Journal of Clinical Oncology 2022 40:16_suppl, 6073-6073 
• Vanita Noronha, Vijay Maruti Patil, Nandini Sharrel Menon, Ajaykumar Singh, Sunil Ramdhan Chopade, Sarbani Ghosh Laskar, Jaiprakash Agarwal, Tejpal Gupta, Ashwini Budrukkar, Vedang Murthy, Neha Mittal, Asawari Patil, Munita Bal, Abhishek Mahajan, Suman Kumar, Vijayalakshmi Mathrudev, Kavita Prakash Nawale, and Kumar Prabhash : Six-year follow-up from the weekly-three-weekly study comparing cisplatin once-a-week to once-every-three-weeks as concurrent chemoradiation for locally advanced head and neck squamous cell carcinoma.Journal of Clinical Oncology 2022 40:16_suppl, 6071-6071 
• Vanita Noronha, Vijay Maruti Patil, Nandini Sharrel Menon, Ajaykumar Singh, Sunil Ramdhan Chopade,Amit Janu, Nilendu Purandare, Rajeev Kumar, Supriya Goud, Sucheta More, Srushti Shah, Reshma Vairage, Akanksha Yadav, Dipti Nakti, Chetan Mudliya, Saurabh Kamble, Shital Chavan, Sonali Sonawane, Shripad Dinanath Banavali, and Kumar Prabhash: Phase III randomized controlled trial comparing chemotherapy to best supportive care in advanced esophageal and gastroesophageal junction cancer.Journal of Clinical Oncology 2022 40:16_suppl, 4065-4065.
• Ajaykumar Singh, Vijay Maruti Patil, Vanita Noronha, Nandini Sharrel Menon, Pankaj Chaturvedi, Vijayalakshmi Mathrudev, Atanu Bhattacharjee, Sunil Ramdhan Chopade, Sujay Srinivas, Somnath Roy, Tanmoy Mondal, Hollis D'souza, Devendra A Chaukar, P. S. Pai, Sudhir Vasudevan Nair, Shivakumar Thiagarajan, Sarbani Laskar, Kavita Prakash Nawale, Sachin Babanrao Dhumal, and Kumar Prabhash: Phase 3 randomized study comparing docetaxel-platinum with docetaxel-platinum-5 fluorouracil as neoadjuvant chemotherapy in technically unresectable oral cancer. Journal of Clinical Oncology 202240:16_suppl, 6013-6013 .
• Anbarasan Sekar, Akhil Rajendra, Vanita Noronha, Smruti Mokal, Vijay Maruti Patil, Nandini Menon, Sunil Chopade, Rajesh Dikshit, Shripad Dinanath Banavali, and Kumar Prabhash: The epidemiological trend of esophageal cancer in Mumbai, India over the past two decades. Journal of Clinical Oncology 202139:15_suppl, e16095-e16095.
• Manju Sengar, Girish Chinnaswamy, Priya Ranganathan, Apurva Ashok, Shilpushp Bhosale, Sanjay Biswas, Pankaj Chaturvedi, Chetan Dhamne, Jigeeshu Divatia, Karishma D’Sa,Hasmukh Jain, Sarbani Laskar, Nirmalya Roy Moulik, Naveen Mummudi, Sindhu Nair,Lingaraj Nayak, Prakash Nayak, Shraddha Patkar, Preeti Pawaskar, Anant Ramaswamy, Omshree Shetty , Arjun Singh , Epari Sridhar , Jayashree Thorat , Rajendra Badwe , C. S. Pramesh , Sunil Chopade and on behalf of the TMH COVID-19 action group*. “Outcomes of COVID-19 and risk factors in patients with cancer”. Nature  Cancer (2022). https://doi.org/10.1038/s43018-022-00363-4
• Vichitra Behel, Anuradha Chougule , Vanita Noronha , Vijay Maruti Patil , Nandini Menon , Ajaykumar Singh, Sunil Chopade , Rajiv Kumar , Srushti Shah , Sucheta More , Shripad Dinanath Banavali , Pratik Chandrani  , Kumar Prabhash : Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC: Clin Lung Cancer 2022 Jul;23(5):410-418. doi: 10.1016/j.cllc.2022.04.002. Epub 2022 Apr 30.
• Noronha, Vanita & Shah, Darshit & Mokal, Smruti & Kapoor, Akhil & Patil, VijayM & Menon, Nandini & Chopade, Sunil & Shah, Srushti & Nawale, Kavita & Banavali, ShripadD & Prabhash, Kumar. (2022). Deviation from standard cancer treatment during the first wave of the COVID-19 pandemic in India: A cross-sectional study. Cancer Research, Statistics, and Treatment. 5. 212. 10.4103/crst.crst_115_22. 
• Case Blog- Rajashree Khot* and Sunil Chopade . “Heparin induced thrombocytopenia due to low molecular heparin” International Journal of Clinical and Medical Imaging ,Volume 2 ,Issue 6- 1000330June, 2015; .doi.org/10.4172/2376-0249.1000330.
• Suresh Kumar Bondili, Ravindra Nandhana, Vanita Noronha, Amit Joshi, Vijay Patil, Nandini Menon, Anuradha Chougule, Omshree Shetty, Rajiv Kumar, Pratik Chandrani, Abhishek Mahajan, Sunil Chopade,Kumar Prabhash. “Resistance mechanisms to epidermal growth factor receptor inhibitors in non-small cell lung cancer” : Cancer Research, Statistics, and Treatment, Year 2020, Volume 3, Issue 4 [p. 801-807] DOI: 10.4103/crst.crst357_20
• George Abraham, Nandini Sharrel Menon, Sunil R Chopade, Vanita Noronha, Vijay M Patil, Amit Joshi, Kumar Prabhash. “A mysterious localized spinal whiteout”: Cancer Research, Statistics, and Treatment, Year 2021, Volume 4, Issue 1 [p. 136-138] DOI: 10.4103/crst.crs36520

Memberships:

Memberships:

• American Society of Clinical Oncology (ASCO), Alexandria
• European Society of Medical Oncology (ESMO)
• Indian Society of Medical and Paediatric Oncology (ISMPO)
• Indian Co-Operative Oncology Network (ICON)
• Association of Medical Consulants (AMC), Mumbai India